Ningde Times ushered in the release of 43.18 billion yuan.

Next week, the A-share market value of more than 98 billion Yuan

Securities Times - Data Treasure statistics, January 3 to 6, the A-share market will be 53 listed companies ushered in the sale of restricted shares of the ban. Calculated on the basis of the latest price of individual shares, the 53 shares of the market value of the release of a total of 98.168 billion yuan.

From the perspective of the scale of the release, Ningde Times and China Mobile are in the forefront, the market value of the release of 43.18 billion yuan, 18.803 billion yuan in turn. The former type of shares released for the directional issue of institutional placement shares, the latter for the first strategic placement shares. National core technology, the world show, cloud aluminum shares, Qiaoyin shares and other stocks of the market value of the release is also more forward, in turn, 5.492 billion yuan, 4.993 billion yuan, 3.492 billion yuan, 3.221 billion yuan.

Data show that the Ningde era this *** counts 10,975,610,000 shares, accounting for 4.49% of the total share capital, the latest market value of 43.18 billion yuan. Public information shows that the unlocking of shares for the company in 2022 to a specific object, holding objects including Guotai Junan, Morgan Stanley, Hong Kong and Shanghai Banking Corporation, including 22 institutional investors. The shares are restricted for six months, with a January 4, 2023 listing and circulation date.

According to the company's announcement, the issue price of the shares is 410 yuan per share. And in the past six months, the company's share price performance is average, July 4 so far the cumulative decline reached 24.61%, the latest price of 393.42 yuan / share.

Data treasure statistics, 9 shares of the proportion of release more than 20%. Qiaoyin shares, Weibo hydraulic, the United States of high proportion of the top, respectively, 73.95%, 72.19%, 70.45%, and the type of the original shareholders of the first restricted shares. There are three other shares of Shenchi electromechanical, Xingtu Xinke, National Core Technology, etc., the proportion of the release of more than 50%.

Smaller proportion of the release of 13 shares of Si Rui Pu, Huashen Science and Technology, Gongda Hi-Tech, the proportion of less than 0.5% of the release of the type of the company's equity incentives for the previous period of the release of the shares. As the incentive program to employee shareholding, accounting for a low proportion of the total share capital, so the impact on the share price of individual stocks is limited.

5 unblocked shares annual net profit is expected to be high

December, the three major indices first rose and then fell. The Shanghai index closed down 1.97%, the Shenzhen Composite Index fell 0.83%, the GEM index rose 0.06%. In the context of the overall market retreat, most of the release of stocks underperformed, 14 shares recorded gains. Nanning Department Store, Prudential Ophthalmology cumulative increase in the front, are more than 20% ; falling stocks, Leit Technology retracement of more than 30%, Xingtu Xinko, Huitong Group, National Core Technology cumulative retracement of more than 15%.

In terms of attention, Ningde Times rating agencies are far ahead of the number of up to 44; Pu Tailai Lai, China Mobile, Aupoint and Si Ruipu and other 4 shares rating agencies are also in the number of more than 20.

According to the consensus forecast of 3 and above institutions, 5 shares of annual net profit is expected to be high, an increase of more than 70% year-on-year. Among them, the national core technology, Minowa growth rate topped, respectively, reached 146.48%, 134.89%; in the Wei shares 92.67%; Ningde Times and PuTaiLai net profit growth rate are more than 76%.

Guochuang Technology main embedded CPU, customized development of security chips for G-end customers. With the policy end of the strong support for Xinchuang, the company's information security business will usher in rapid growth. In addition, automotive MCU is also expected to drive the company's sustained high growth. Meinova, on the other hand, continues to make efforts in the field of CDMO and preparations, and the varieties of APIs and customers continue to be enriched, which will construct the future performance growth point. At present, the company has achieved international and domestic commercialization of more than 20 product categories, focusing on core therapeutic areas.